TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Meeting recommendations for physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH value in gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total hemostatic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: anti-paralysis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of complete response (no emesis, no rescue medication, no study withdrawal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: non-fatal CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean maximum PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving behavior changes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fiberoptic view quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dairy intake frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in early-responding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in late-responding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-Day lethality
Endpoint domain: Mortality/survival
Primary endpoint: CC recovery after TLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of gestational diabetes mellitus (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean gestation at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of spontaneous vaginal delivery at term
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Use rates for lumbar spine imaging procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Variability in use rates for lumbar spine imaging procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: overall cardiovascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fetoplacental thrombotic vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: fetal carriership of FVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: objective treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: final visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of retreatments required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in YIAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate increment in response to exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of angina attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subjective waiting time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean platelet increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Type I muscle fiber area (MFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Myonuclear number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quadriceps cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: thickness ratio on the affected diaphragm thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: inspiratory muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Delayed verbal recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Memory intrusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peri-implant plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertical and horizontal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RNA PCR sensitivity at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RNA PCR sensitivity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median viral load of RNA-positive specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 4-fold titer rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recognition of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Passage of flatus within the first 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in EDSSpyr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in selective attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AEXT strength gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poorer sleep quality score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: higher external eating score
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: higher perceived stress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of migraine-related days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ventilator-free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total BI and FIM scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of severe EA
Endpoint domain: Adverse events/effects
Primary endpoint: first analgesic requirement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total amount of opioid used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in communicative behavior of oncologists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent in moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of overweight or obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vomiting from 0 to 72 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with PONV management
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stability of mutational archive in HIV-1 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent bleeding within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Subjective measure of arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: acute or late effects of radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rate and arterial blood pressure decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sclerostin concentrations in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DeltaFVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DeltaFEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DeltaPEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of ischemia-driven target-vessel revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Defibrillation threshold (DFT) voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: occurrence of respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of nasal discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red blood cell volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: normalized train-of-four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of adjacent vertebral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: days quit
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Severe Intraoperative Floppy Iris Syndrome (IFIS)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in psychotic experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in emotional dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Biphasic defibrillation threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Total Weight Loss (TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean CDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in median asthma score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leucocyte concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive and negative symptoms of schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma iGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary iGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nonadherence to antibiotic prescriptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean changes in YMRS total score at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from cure to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women remaining BV-free at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pPROM-delivery period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate-to-vigorous total physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical fatigue levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cholesterol management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean MBP concentrations after TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PHA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PPD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healing of ulcerative wound and fresh wound granulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrent hemorrhoids with symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rate of serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post-procedure pain VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-procedure anxiety VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in ocular itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ocular redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physicians' impression of overall improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥3% weight loss at 9-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in C1,2C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean yearly radiographic progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean disease activity over 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flexibility level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypoglycemic episodes per patient per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walk distance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of the development of clinically definite multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: Volume of brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of new or enlarging lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean reduction in total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment efficacy in peritoneal dialysis associated peritonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean reduction in intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death or survival in vegetative state
Endpoint domain: Mortality/survival
Primary endpoint: functional outcome improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of overall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal outcome (side effects)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar's score at first and fifth minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of surgical technique
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain evaluation on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients experiencing no emetic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Masked quality assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of treatment benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incorporation of trial quality into analyses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undetectable HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of residents aged 65 and older receiving pneumococcal vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cost for a life-year saved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Any CRC screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polyp identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative healing rates of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of ovarian cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 17beta-estradiol levels on Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum 17beta-estradiol levels on Day 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Uptake of breast screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Tongue muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predominant pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal knee function at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to pass return to sport criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEP PtP-amplitude from UV(B)-inflamed skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high CAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma virus set point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) of 21 mm Hg or less without medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: platelet count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Orgasmic function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF-related symptoms preventing normal functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hospitalization due to AF-related symptoms
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment with oral vitamin K antagonists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean alpha angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of children requiring treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Free plasma haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of ovulating patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Thicker endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: overall flushing severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zero contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes